George Tetz, MD, Ph.D
George Tetz, MD, PhD, is CEO of CLS Therapeutics Inc with leadership experience in several industry, scientific, and non-profit organizations. Throughout his career, George Tetz has focused on applying cutting-edge genomic approaches to a variety of medical problems. Dr. G. Tetz has been in the background of numerous ground-breaking studies in the field of the role of cell-free DNA in different human diseases, and microbiology.
Dr. G. Tetz has been focused on discovering novel regulation pathways linking gut-microbiome cell-free DNA to oncology and neurodegenerative diseases. Prior to joining CLS-Therapeutics, George Tetz worked in numerous collaborative drug discovery programs. In total, Dr. George Tetz has over 18 years of experience in fundamental science and drug development. He is currently a member of the American Society for Microbiology and New York Academy of Sciences.
Dmitry Genkin, MD
Since 2006, Dr. Genkin has served as the Chairman of the Board of Pharmsynthez plc (MICEX: LIFE), an Eastern European pharmaceutical company specializing in the development of oncology drugs and manufacture of science-intensive substances. Since 2002, Dr. Genkin has served as a director of and on the scientific advisory board of Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics. Dr Genkin is co-founder and former director of VBI Vaccines Inc (NASDAQ: VBIV) – a clinical-stage biopharmaceutical company.
Victor Tetz, MD, Ph.D
Dr. Victor Tetz has over 25 years of experience in drug discovery and development. He is co-founder of Human Microbiology Institute – a NY-based private scientific research organization. The tasks of the Human Microbiology Institute include researching host-microflora interactions to elucidate the role of the microbiota, cell-free DNA, non-living genetic elements, and phagobiota in different human pathologies, including oncology and longevity. Through his carrier V.Tetz served as a senior investigator and collaborator for microbiology research projects for NASA, Abbott, Sanofi, Pepsi, Gen3Partners, Dole, Procter & Gamble.
Dr. Michelle Welborn
Dr. Michelle Welborn, serves as a pharmaceutical consultant and provides regulatory consulting to manage the project in FDA. Michelle Welborn holds a Doctor of Pharmacy degree from Campbell University School of Pharmacy.
Michelle has 15 years experience in pharmaceuticals as a liaison in Medical and Regulatory Affairs for both Astra-Merck and Sanofi –Aventis Pharmaceuticals, and as Clinical Pharmacy Manager for a Health Maintenance Organization (HMO) , and as a Pharmacy Practice resident at Wake Forest University Baptist Medical CenterShe has participated in workshops and consortiums organized by the NIH (National Institutes of Health), the National Organization of Rare Diseases (NORD), the International Congress of Rare Diseases (ICORD), and the Centers for Disease Control (CDC), the Epilepsy Foundation of America, and the Australian Dravet syndrome Family Day.
She served for two years as the Professional Advisory Board Chair for the IDEA League before founding ICE. She currently serves on the Professional Advisory Boards for the Charlie Foundation and Lennox-Gastaut Syndrome Foundation.
Mr. Brad Rosenblum
Mr. Rosenblum is Chief Financial Officer of CLS Therapeutics, Inc. Brad has over twenty years’ experience in finance and management across a variety of industries. In this position, his primary responsibilities are to oversee the company’s day-to-day financial activities.
Brad Rosenblum, CPA, is CFO of CLS Therapeutic Inc. Brad is a high impact, results-oriented, operationally focused CFO with significant influence on the financial performance of both fast- growing start-ups and operating companies. Brad has a demonstrated record of building lean, scalable operations resulting in improved processes and reduced costs with a history of 15 acquisitions and 5 exits.
Casey Maguire, Ph.D
Casey Maguire is an assistant professor at Harvard Medical School (HMS) and assistant investigator in the department of Neurology at the Massachusetts General Hospital (MGH). Casey received his PhD from the department of Microbiology and Immunology at the University of Rochester School of Medicine and Dentistry in 2006. He was a postdoctoral fellow at HMS starting in 2006, then an Instructor, and an assistant professor in 2013.
Casey’s main interests lie in the development of better gene therapy vectors, especially adeno-associated virus (AAV). His laboratory has discovered and developed new gene delivery systems to overcome in vivo barriers that currently prevent efficient therapy in patients. In collaboration with disease experts, he has developed preclinical therapies for hereditary hearing loss, hemophilia, and neurodegenerative diseases. He has currently published 38 peer-reviewed articles mainly in the field of gene therapy and gene delivery and has three issued patents.